drugset / Trial / NCT06918015
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Previously untreated patients with follicular lymphoma are treated with the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles.
Timeline
- Start
- 2025-05-01
- Primary completion
- 2028-05-01
- Completion
- 2030-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 750 unknown | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Background | Prednisolone | Other / unclassified | 30 mg | Oral |
| Background | Vindesine | Small molecule | 3 mg/m2 | Intravenous |